Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)

Market Cap	7.83B +6.6%
Revenue (ttm)	751.12M -10.1%
Net Income	184.84M -28.2%
EPS	0.22 -30.7%
Shares Out	828.30M
PE Ratio	42.69
Forward PE	35.66
Dividend	0.10 (1.06%)
Ex-Dividend Date	Jul 17, 2025

Volume	5,822,157
Average Volume	5,610,319
Open	9.18
Previous Close	9.22
Day's Range	9.18 - 9.47
52-Week Range	6.94 - 12.51
Beta	-0.19
RSI	42.27
Earnings Date	Apr 29, 2026

About SHA:603229

Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, it offers development and manufacturing services to the pharmaceutical, cosmetics, and nutritional industries. The company was founded in 2010 and is b...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 1,219
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603229

Financial Performance

In 2024, SHA:603229's revenue was 795.29 million, a decrease of -2.63% compared to the previous year's 816.77 million. Earnings were 206.79 million, a decrease of -18.55%.